Effect of Hepatosteatosis on the Virological Response in Entecavir and Tenofovir Therapies

Basit Öğe Kaydı
dc.authoridMeric Koc, Meliha/0000-0002-0563-6900
dc.authoridTulek, Necla/0000-0002-3952-4982
dc.authoridHakyemez, Ismail Necati/0000-0001-6133-9604
dc.authoridCelik, Ilhami/0000-0002-2604-3776
dc.authoridTuncer Ertem, Gunay/0000-0001-8760-0030
dc.authoridDemirturk, Nese/0000-0002-6186-2494
dc.authoridUral, Onur/0000-0003-1355-7572
dc.contributor.authorKorkmaz, Pinar
dc.contributor.authorDemirturk, Nese
dc.contributor.authorBatirel, Ayse
dc.contributor.authorTulek, Necla
dc.contributor.authorOzguler, Muge
dc.contributor.authorHarman, Rezan
dc.contributor.authorCinar, Gule
dc.date.accessioned2024-11-07T13:35:36Z
dc.date.available2024-11-07T13:35:36Z
dc.date.issued2019
dc.departmentNiğde Ömer Halisdemir Üniversitesi
dc.description.abstractObjective: Both chronic hepatitis B (CHB) and hepatosteatosis may lead to necroinflammation in liver. Therefore, the presence of hepatosteatosis might negatively affect the efficacy of antiviral therapy. We aimed to determine the effect of hepatosteatosis on virological response in patients with CHB receiving entecavir (ETV) and tenofovir (TDF) treatment. Methods: The study was designed retrospectively. All patients receiving antiviral therapy due to CHB in the departments of Infectious Diseases and Clinical Microbiology of 29 different hospitals between January 2012 and June 2017 were searched by examining medical records. Results: A total of 1069 patients were included. Six hundred and fifty of the patients had been receiving TDF and 419 of them had been receiving ETV. The rate of virological response obtained at the 48'h week of TDF was higher in patients with steatosis (p=0.029). Virological response at the 24th week and 48th week of ETV were higher in the patients without steatosis (p=0.001). TDF and ETV therapies were compared in the patients with hepatosteatosis and it was found that the virological response at 48th week was higher in the TDF group. Conclusion: Although steatosis has an effect on virological response in the short-term results of nucleos(t)ide therapy, it does not have any effect on virological response in the long-term results.
dc.identifier.doi10.5152/kd.2019.73
dc.identifier.endpage274
dc.identifier.issn1301-143X
dc.identifier.issn1309-1484
dc.identifier.issue3
dc.identifier.scopus2-s2.0-85077860443
dc.identifier.scopusqualityQ4
dc.identifier.startpage265
dc.identifier.urihttps://doi.org/10.5152/kd.2019.73
dc.identifier.urihttps://hdl.handle.net/11480/16566
dc.identifier.volume32
dc.identifier.wosWOS:000511173500009
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isotr
dc.publisherAves
dc.relation.ispartofKlimik Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241106
dc.subjectFatty liver
dc.subjectentecavir
dc.subjecttenofovir
dc.titleEffect of Hepatosteatosis on the Virological Response in Entecavir and Tenofovir Therapies
dc.title.alternativeHepatosteatozun entekavir ve tenofovir tedavilerinde virolojik yanıta Etkisi
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu